ACT is not limited to this setting, however, and anti-CD19 CAR therapy in the absence of transplant and in the autologous setting has demonstrated success in heavily pretreated and refractory CLL patients[80]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.